Navigation Links
BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Date:11/19/2013

BETHLEHEM, Pa., Nov. 19, 2013 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), has been contracted by BHR Pharma to develop an in-field nasally applied formulation of Progesterone for traumatic brain injury (TBI).  BHR is pioneering this treatment and is well into their study, SyNAPSe® (Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries), a global, Phase 3, multi-center pivotal trial in severe TBI using a parenteral formulation that was independently developed.  According to Mark Mitchnick, MD, Particle Sciences' CEO, "Particle Sciences focuses on formulation design and manufacturing.  Our clients often face challenging delivery issues so the dosage forms we work with frequently require a high level of engineering and the simplification of complex formulation challenges to commercially viable products.  In this case, the challenge was achieving rapid onset under conditions of true duress, trauma.  The product had to be versatile and durable.  BHR are world leaders in this therapeutic approach and working with their technical team we have been able to design a dosage form that meets their needs.  We look forward to helping BHR bring this very important product into the clinic and through to commercialization."        

Particle Sciences is an integrated pharmaceutical CDMO.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and ma
'/>"/>

SOURCE Particle Sciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Maximizing Production Capacity for Growth - Finding 5% for Pharmaceutical or Biotech Companies through Facility Optimization, a New Life Science Webinar from Xtalks
2. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
3. IPISC announces IP insurance for the Biotechnology/Pharma Industry
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
6. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
7. HealthEconomics.Com Distinguished Again as Top Influencer at the International Society for Pharmacoeconomics and Outcomes Research 16th Annual European Congress in Dublin
8. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
9. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
10. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
11. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... compound in sufficient and rapidly produced yields, potentially ... could boost semiconductor capabilities for large-area applications. , ... the first heterometallic gallium-indium hydroxide nanocluster was the ... of nitrosobenzene. , The substitute was identified during ...
... 31 VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), ... treatment of venous reflux disease, today,announced the hiring of ... Chief Medical Officer., Dr. Smeets joins VNUS with ... Dr. Smeets served as the Head of Clinical Affairs ...
... RANCHO CORDOVA, Calif., Oct. 31 ThermoGenesis,Corp. (Nasdaq: ... and store adult stem cells, announced today it will ... 30, 2008, on,Thursday, November 6, 2008., Company,s Conference ... call Thursday, November 6, 2008 at,2:00 PM Pacific (5:00 ...
Cached Biology Technology:New nanocluster to boost thin films for semiconductors 2VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008 2
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... In neurodegenerative diseases, clumps of insoluble proteins appear in ... to each disease, such as amyloid beta in Alzheimer,s ... many other insoluble proteins that are normally present in ... these other proteins were thought to be accidental inclusions ...
... has detected and quantified novel small RNAs in human ... molecules, confirming a long-held but unproven hypothesis that mammalian ... molecules directly. The findings were reported in Nature ... School of Medicine , Helicos Biosciences Corp., Integromics Inc., ...
... received the prestigious Coulter Foundation Translational Awards for promising ... The Coulter program provides funding for ... Initial funding for each professor will be at ... NJIT Associate Professor Treena Arinzeh will receive funding for ...
Cached Biology News:Proteins linked with Alzheimer's, other neurodegenerative diseases found to clump in normal aging 2Proteins linked with Alzheimer's, other neurodegenerative diseases found to clump in normal aging 3Human cells can copy not only DNA, but also RNA, says team from Pitt, Helicos BioSciences 2Stem cell, artificial liver research receives Coulter Foundation funding at NJIT 2
... Dithiothreitol DTT ... INERT GAS. Purity: ≥99% ... metals: Absorbance: (100 ... Soluble in EtOH or H ...
... White solid.. PACKAGED UNDER INERT GAS. ... reaction is "driven" to completion. A protective agent ... found in many other preparations. Blocks the lethal ... by titration. Contaminants: Heavy metals: ≤1 ...
... Faster speeds, highest precision, more user-friendliness ... concept: this is the definition of the ... years nucleic acid research has been developing ... required of PCR Systems. To keep ...
... The recent sequencing of Salmonella genomes ... enterica Typhimurium ORFmer PCR* primer pairs. The ... of a single chromosome (4,857,432 bp; 4,440 ... 107 ORFs). These ORFmers from Sigma-Genosys have ...
Biology Products: